Genzyme Plans Campath MS Launch In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.
You may also be interested in...
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Teva/Active Biotech Initiate Phase III Program For Laquinimod Oral MS Therapy
Firm enters Phase III along with Acorda, Biogen Idec, others in race to bring first oral MS agent to market.